Robert Laboratory
Therapeutic Antibodies
for Inflammation
Welcome to the Robert Lab
Our objective is to develop new classes of therapeutic mAbs against difficult proteins (i.e GPCRs) using cutting edge technologies in mAbs development, engineering and pre-clinical validation.
We're part of the Monash Biomedicine Discovery Institute, and a member of the Immunity Program
and the Department of Physiology, and Biochemistry & Molecular Biology
Dr Remy Robert
My global research connections, partners and funding can be viewed on my Monash Research Profile.
If you are a student interested in doing research in our lab, visit Supervisor Connect.
Click the links below to connect with me on ORCID, Google Scholar and LinkedIn.
Our research
Antibodies are the fastest growing drug class, with more than 60 antibody drugs approved. They have a major impact on human health, especially in oncology, autoimmunity and inflammatory diseases. New opportunities for antibody drug development may be possible by generating antibodies against difficult targets. Our objective is to develop new classes of therapeutic mAbs using cutting edge technologies in mAbs development, engineering and pre-clinical validation. We have demonstrated that targeting specific GPCRs was an innovative approach for the treatment of various inflammatory and autoimmune disorders. Our goal is to move academic science into translation.
Lab members
We are committed to excellence in research.
Join Our Lab
We're always interested in collaborating with bright and motivated researchers, clinicians and industry. Whether you want to research, study or partner with us to accelerate our discoveries, find out about the work we do.